Evolution of the Average Target: bioMérieux

Evolution of the Target Price: bioMérieux

Changes in Analyst Recommendations: bioMérieux

71.YTUCQWBQlVJqxABtAeMbrakPyRnSCAQi58uqt5Vii7Q.C3pyDygp2ytdp1EpNYl2nfBfv3OlY0kSra3w4s9QwMMRcXsbLQXWOFq0MA~d194e1e4fbac0f20846d6ab3267d8d64
Jul. 16 MedTech facing a three-front squeeze Alphavalue
Jul. 10 Sadif Investment Analytics Upgrades bioMérieux to Hold Rating MT
Jun. 24 Barclays Cuts BioMérieux's PT, Affirms Equalweight Rating MT
Jun. 23 Morgan Stanley Downgrades bioMérieux to Underweight, Cuts PT MT
Jun. 22 RBC Capital Cuts bioMérieux PT, Affirms Sector Perform Rating MT
Jun. 01 BioMérieux in the red following UBS downgrade Zonebourse
Jun. 01 UBS Downgrades bioMérieux to Neutral, Cuts PT MT
Jun. 01 UBS downgrades bioMérieux to neutral, shares retreat Zonebourse
Jun. 01 EasyJet Soars on Takeover Rumors, Pan African Slows Down Zonebourse
Jun. 01 French Analyst Ratings: UBS downgrades Biomerieux, Soitec remains in favor Zonebourse
Apr. 24 Deutsche Bank Downgrades bioMérieux to Hold, Cuts PT MT
Apr. 23 BioMerieux: Disappointing Q1 and lower guidance undermine investor confidence Alphavalue
Apr. 13 RBC Capital Favors Diasorin Over bioMérieux Zonebourse
Apr. 10 AlphaValue Urges Patience on bioMérieux, Maintains Buy Rating Zonebourse
Mar. 05 TP ICAP Midcap Downgrades BioMérieux to Hold, Cuts PT MT
Mar. 02 BioMérieux Still Has Upside Potential, Says All Invest Securities Zonebourse
Feb. 27 BioMerieux: 2025 promise delivered; 2026 targets in sight Alphavalue
Feb. 02 Oddo BHF Voices Concerns Over Currency Impact and Weaker Flu Season for bioMérieux Zonebourse
Jan. 20 TP ICAP Midcap Upgrades bioMérieux to Buy MT
Nov. 10 UBS Maintains Buy Rating on BioMérieux, Confirms Price Target Zonebourse
Nov. 05 Analysts Maintain Buy Ratings on bioMérieux After Q3 Results Zonebourse
Nov. 05 Invest Securities Upgrades bioMérieux to Buy MT
Nov. 05 BioMérieux: Invest Securities upgrades stock after quarterly results Zonebourse
Nov. 04 Biomérieux Q3 earnings miss prompts softer 2025 guidance Alphavalue
Nov. 04 Stifel remains bullish on BioMérieux after trading update. Zonebourse

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+16.74%
+12.34%
+3.75%
-15.58%
+38.78%
+71.65%
+4.49%
+20.62%
Average +19.10%
Weighted average by Cap. +15.87%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
14
Last Close Price
70.40EUR
Average target price
82.19EUR
Spread / Average Target
+16.74%
High Price Target
105.00EUR
Spread / Highest target
+49.15%
Low Price Target
64.00EUR
Spread / Lowest Target
-9.09%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Sadif Investment Analytics
Barclays
Morgan Stanley
RBC Capital Markets
UBS
Deutsche Bank Research
alphavalue Anas Patel
TP ICAP Midcap
Invest Securities
CIC Market Solutions
Gilbert Dupont
JPMorgan
AlphaValue/Baader Europe
ODDO BHF
Deutsche Bank Securities
Stifel Nicolaus
Berenberg Bank
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
14
Last Close Price
70.40EUR
Average target price
82.19EUR
Spread / Average Target
+16.74%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BIM Stock
  4. Consensus bioMérieux